Market revenue in 2023 | USD 158.0 million |
Market revenue in 2030 | USD 535.3 million |
Growth rate | 19% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60.38% in 2023. Horizon Databook has segmented the North America plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The high prevalence of diseases in the region, rise in research funding, and presence of numerous pharmaceutical & biopharmaceutical firms in the region are all key factors driving the Plasmid DNA (pDNA) contract manufacturing market in North America.
The development of advanced treatments has had a significant impact on the biopharmaceutical sector's transformation as well as the paradigm of treating a number of serious & rare diseases. The growing popularity of Cell & Gene Therapies (CGTs) also propels growth of the market in the region.
In fact, more than 400 companies in North America are actively working to develop and research on CGTs. Among these therapies, many widely use pDNA as a vector for gene therapies and DNA vaccines against infectious, acquired, & genetic diseases, including cancer and COVID-19.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America plasmid dna contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into North America plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account